Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/21932
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorNETO, Adalberto Studart-
dc.contributor.authorNETO, Herval R. Soares-
dc.contributor.authorSIMABUKURO, Mateus M.-
dc.contributor.authorSOLLA, Davi J. F.-
dc.contributor.authorGONCALVES, Marcia R. R.-
dc.contributor.authorFORTINI, Ida-
dc.contributor.authorCASTRO, Luiz H. M.-
dc.contributor.authorNITRINI, Ricardo-
dc.date.accessioned2017-10-24T13:18:50Z-
dc.date.available2017-10-24T13:18:50Z-
dc.date.issued2017-
dc.identifier.citationALZHEIMER DISEASE & ASSOCIATED DISORDERS, v.31, n.3, p.239-243, 2017-
dc.identifier.issn0893-0341-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/21932-
dc.description.abstractBackground: Rapidly progressive dementia (RPD) is usually associated with Creutzfeldt-Jakob disease, a fatal condition. Current advances in the understanding of immune-mediated diseases allow the diagnosis of previously unrecognized treatable RPDs. Objective of the Study: The objective of the study was to describe the prevalence and causes of RPD in a neurology service, identifying potentially reversible causes. Methods: We carried out a cross-sectional evaluation of all patients admitted to the neurology unit of a tertiary hospital in Brazil between March 2012 and February 2015. We included patients who had progressed to moderate or severe dementia within a few months or up to 2 years at the time of hospitalization, and used multivariable logistic regression analysis to identify factors associated with a favorable outcome. Results: We identified 61 RPD (3.7%) cases among 1648 inpatients. Mean RPD patients' age was 48 years, and median time to progression was 6.4 months. Immune-mediated diseases represented the most commonly observed disease group in this series (45.9% of cases). Creutzfeldt-Jakob disease (11.5%) and nonprion neurodegenerative diseases (8.2%) were less common in this series. Outcome was favorable in 36/61 (59.0%) RPD cases and in 28/31 (89.3%) of immune-mediated cases. Favorable outcome was associated with shorter time from symptom onset to diagnosis and abnormal cerebrospinal fluid findings. Conclusions: Immune-mediated diseases were the most common cause of RPD in this series. Timely evaluation and diagnosis along with institution of appropriate therapy are required in RPD, especially in view of potentially reversible causes.-
dc.language.isoeng-
dc.publisherLIPPINCOTT WILLIAMS & WILKINS-
dc.relation.ispartofAlzheimer Disease & Associated Disorders-
dc.rightsrestrictedAccess-
dc.subjectrapidly progressive dementia-
dc.subjectprion diseases-
dc.subjectCreutzfeldt-Jakob disease-
dc.subjectimmune-mediated encephalopathies-
dc.subject.othercreutzfeldt-jakob-disease-
dc.subject.otheralzheimers-disease-
dc.subject.otherreferral-center-
dc.subject.otheronset dementia-
dc.subject.otherdiagnosis-
dc.subject.otherpathogenesis-
dc.subject.otherguidelines-
dc.subject.otherathens-
dc.titleRapidly Progressive Dementia: Prevalence and Causes in a Neurologic Unit of a Tertiary Hospital in Brazil-
dc.typearticle-
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINS-
dc.identifier.pmid27849640-
dc.subject.wosClinical Neurology-
dc.subject.wosPathology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage239-
hcfmusp.description.endpage243-
hcfmusp.description.issue3-
hcfmusp.description.volume31-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84995376688-
hcfmusp.origem.idWOS:000408516100009-
hcfmusp.publisher.cityPHILADELPHIA-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAppleby BS, 2011, EXPERT OPIN PHARMACO, V12, P1, DOI 10.1517/14656566.2010.514903-
hcfmusp.relation.referenceBien CG, 2012, BRAIN, V135, P1622, DOI 10.1093/brain/aws082-
hcfmusp.relation.referenceBROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504-
hcfmusp.relation.referenceChitravas N, 2011, ANN NEUROL, V70, P437, DOI 10.1002/ana.22454-
hcfmusp.relation.referenceEurelings LSM, 2010, J NEUROL SCI, V295, P131, DOI 10.1016/j.jns.2010.04.020-
hcfmusp.relation.referenceFermo O.P., 2014, NEUROL CLIN PRACT, V4, P493-
hcfmusp.relation.referenceGeschwind MD, 2008, ANN NEUROL, V64, P97, DOI 10.1002/ana.21430-
hcfmusp.relation.referenceGeschwind MD, 2007, NEUROL CLIN, V25, P783, DOI 10.1016/j.ncl.2007.04.001-
hcfmusp.relation.referenceGeschwind Michael D, 2010, Continuum (Minneap Minn), V16, P31, DOI 10.1212/01.CON.0000368211.79211.4c-
hcfmusp.relation.referenceHoftberger R, 2015, CURR OPIN ONCOL, V27, P489, DOI 10.1097/CCO.0000000000000222-
hcfmusp.relation.referenceHuang N, 2003, NEUROLOGY, V61, P354-
hcfmusp.relation.referenceJosephs KA, 2009, ARCH NEUROL-CHICAGO, V66, P201, DOI 10.1001/archneurol.2008.534-
hcfmusp.relation.referenceKelley BJ, 2009, COGN BEHAV NEUROL, V22, P22, DOI 10.1097/WNN.0b013e318192cc8d-
hcfmusp.relation.referenceLancaster E, 2012, NAT REV NEUROL, V8, P380, DOI 10.1038/nrneurol.2012.99-
hcfmusp.relation.referenceMcKeon Andrew, 2010, Continuum (Minneap Minn), V16, P80, DOI 10.1212/01.CON.0000368213.63964.34-
hcfmusp.relation.referenceMcKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005-
hcfmusp.relation.referenceO'Toole O, 2013, SEMIN NEUROL, V33, P357, DOI 10.1055/s-0033-1359318-
hcfmusp.relation.referencePapageorgiou SG, 2009, ALZ DIS ASSOC DIS, V23, P347, DOI 10.1097/WAD.0b013e31819e6b28-
hcfmusp.relation.referencePapageorgiou SG, 2009, ALZ DIS ASSOC DIS, V23, P337, DOI 10.1097/WAD.0b013e31819e099b-
hcfmusp.relation.referencePaterson RW, 2012, ARCH NEUROL-CHICAGO, V69, P1578, DOI 10.1001/2013.jamaneurol.79-
hcfmusp.relation.referencePaterson RW, 2012, NEUROL CLIN PRACT, V2, P187-
hcfmusp.relation.referencePoser S, 1999, BRAIN, V122, P2345, DOI 10.1093/brain/122.12.2345-
hcfmusp.relation.referenceRosenbloom MH, 2009, CURR NEUROL NEUROSCI, V9, P359, DOI 10.1007/s11910-009-0053-2-
hcfmusp.relation.referenceRosenbloom MH, 2011, NEUROLOGIST, V17, P67, DOI 10.1097/NRL.0b013e31820ba5e3-
hcfmusp.relation.referenceSala I, 2012, ALZ DIS ASSOC DIS, V26, P267, DOI 10.1097/WAD.0b013e3182368ed4-
hcfmusp.relation.referenceSchmidt C, 2011, ARCH NEUROL-CHICAGO, V68, P1124, DOI 10.1001/archneurol.2011.189-
hcfmusp.relation.referenceShields J, 2010, J NEUROPATH EXP NEUR, V69, P533-
hcfmusp.relation.referenceTitulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1-
hcfmusp.relation.referenceTschampa HJ, 2001, J NEUROL NEUROSUR PS, V71, P33, DOI 10.1136/jnnp.71.1.33-
hcfmusp.relation.referenceVitali P, 2011, NEUROLOGY, V76, P1711, DOI 10.1212/WNL.0b013e31821a4439-
hcfmusp.relation.referenceWorld Health Organization, 1998, GLOB SURV DIAGN THER, P9-
hcfmusp.relation.referenceWILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134-
hcfmusp.relation.referenceZuliani L, 2012, J NEUROL NEUROSUR PS, V83, P638, DOI 10.1136/jnnp-2011-301237-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus14-
hcfmusp.scopus.lastupdate2022-08-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MNE
Departamento de Neurologia - FM/MNE

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/15
LIM/15 - Laboratório de Investigação em Neurologia

Artigos e Materiais de Revistas Científicas - LIM/45
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_NETO_Rapidly_Progressive_Dementia_Prevalence_and_Causes_in_a_2017.PDF
  Restricted Access
publishedVersion (English)122.83 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.